Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session

IMI
Session Type: Workshop

W14--Management of Infections & Inflammation in CF

Thursday, October 23, 2025
10:15 AM - 12:15 PM PDT
Location:423-425

Management of infections and inflammation in cystic fibrosis (CF) requires a multifaceted approach that considers therapeutic interventions, the host immune response, the unique lung microenvironment, and the dynamic interplay of microbial communities. This session will explore strategies from each of these facets with the goal of improving infection outcomes and taming inflammation. Presentations will cover innovative strategies to enhance antimicrobial efficacy, including phage therapy and antibiotic potentiation, while also examining how viral co-infections and mucin accumulation shape microbial ecology and host-pathogen interactions. By integrating insights from microbiology, immunology, and airway physiology, attendees will gain understanding of novel molecular strategies to optimize infection management in CF, tailored to the patient’s infection status and lung environment.

Learning Objectives:

  • 1. Identify the factors influencing infection persistence and inflammation in cystic fibrosis, including host responses, microbial interactions, and the lung environment.
  • 2. Describe how viral infections and mucus environment can alter bacterial virulence and impact disease progression.
  • 3. Differentiate the potential advantages and challenges of novel therapies, including phage therapy, antibiotic adjuvants, and antiviral agents, in managing CF infections.

Presentations:

  • 10:15 AM - 12:15 PM PDT
    W14.1- Leveraging bacterial iron uptake to potentiate antibiotic efficacy

    Speaker: Anna Clara Milesi Galdino – Cedars-Sinai Medical Center

  • 10:15 AM - 12:15 PM PDT
    W14.2- Co-morbidities alter immune response and drive increased Pseudomonas abundance during viral infection in the airways of people with cystic fibrosis

    Speaker: Yasmin Hilliam, PhD – Geisel School of Medicine at Dartmouth

  • 10:15 AM - 12:15 PM PDT
    W14.3- Using experimental evolution to weaponize bacteriophages for chronic Burkholderia cenocepacia infections in patients with cystic fibrosis

    Speaker: Anna Li – University of Pittsburgh

  • 10:15 AM - 12:15 PM PDT
    W14.4- Increased concentrations of mucin impede Staphylococcus aureus growth in synthetic cystic fibrosis sputum medium

    Speaker: Caitlyn Sebastian – University of Alabama at Birmingham

  • 10:15 AM - 12:15 PM PDT
    W14.5- AVP10 is a novel anti-viral peptide with reduced activity in the CF airway.

    Speaker: Matthew Biggart, PhD – Kansas University Medical Center